"We really try to limit the amount of tissue we resect and what we do in patients who've had radiation," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses patient selection for ...
18F-DCFPyL PET/CT shows high detection rates in biochemically recurrent prostate cancer with low PSA levels, suggesting its utility in early metastatic disease identification. The study included 129 ...
"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD. The Society of Benign Prostatic Disease ...
“We took the urine from those patients, and we tested to see if we can predict their gemcitabine metabolism capability. We were able to predict it pretty accurately,” says Laura Bukavina, MD, MPH. In ...
"We found that actually, many, many physicians were not reporting PSA doubling time," says Alicia Morgans, MD, MPH. In this video, Alicia Morgans, MD, MPH, gives an overview of the study “Impact of ...
“We took the urine from those patients, and we tested to see if we can predict their gemcitabine metabolism capability. We were able to predict it pretty accurately,” says Laura Bukavina, MD, MPH.
Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results